Skip to main content
Erschienen in: Archives of Virology 5/2018

05.02.2018 | Original Article

Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C

verfasst von: Dan Yan Zhu, Xiao Zhao Deng, Yu Meng Zhu, Guo Tao Li, Guo Qiang Zhang, Ling Ju Wang, Jing Hai Zhang, Wen Xiao, Zhen Xian Zhou, Wei Liang Ding

Erschienen in: Archives of Virology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. The outcomes of both spontaneous HCV clearance and response to therapy depend on both viral and host factors. To investigate the influence of polymorphisms of IL-28B rs12979860 and TBX21 rs17250932, rs4794067 as well as viral factors (HCV genotype, F protein) on the outcome of HCV infection, we genotyped 565 patients with chronic HCV infection, 191 patients spontaneously resolved from HCV infection, 359 healthy controls and 383 treatment-naïve CHC patients with pegylated interferon-α and ribavirin (PEG IFN-α/RBV). Results showed that TBX21 rs4794067 variant genotypes significantly correlated with increased risk of HCV chronic infection (dominant model: OR = 5.690, 95% CI = 2.024-16.000) and susceptibility (dominant model: OR = 5.658, 95% CI = 2.514-12.735). We also found that the rs12979860, rs2227982 and rs36084323 polymorphisms showed no significant associations with susceptibility or spontaneous clearance of HCV in the anti-F antibody subgroup; however, the anti-F antibody positive subgroup might show an increased risk of N-SVR (all P < 0.001). Our results demonstrate that variant factors in both the host and pathogen are commonly important for HCV clearance. In addition rs4794067 and F protein status may be strong predictive markers in the Chinese population.
Literatur
1.
Zurück zum Zitat Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalencee. Hepatology 57:1333–1342CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalencee. Hepatology 57:1333–1342CrossRefPubMed
2.
Zurück zum Zitat Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association (2015) Guidelines for the prevention and treatment of chronic hepatitis C: a 2015 update. Chin J Liver Dis 23:888–905 Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association (2015) Guidelines for the prevention and treatment of chronic hepatitis C: a 2015 update. Chin J Liver Dis 23:888–905
3.
Zurück zum Zitat Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36:S35–S46PubMed Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36:S35–S46PubMed
4.
Zurück zum Zitat Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77–87CrossRefPubMed Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77–87CrossRefPubMed
5.
Zurück zum Zitat Gower E, Estes CC, Hindman S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:45–57CrossRef Gower E, Estes CC, Hindman S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:45–57CrossRef
6.
Zurück zum Zitat Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP (2009) Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 16:75–90CrossRefPubMedPubMedCentral Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP (2009) Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 16:75–90CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K (2011) Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 43:455–458CrossRefPubMed Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K (2011) Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 43:455–458CrossRefPubMed
8.
Zurück zum Zitat Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50CrossRefPubMed Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50CrossRefPubMed
9.
Zurück zum Zitat Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801CrossRefPubMedPubMedCentral Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401CrossRefPubMed Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401CrossRefPubMed
11.
Zurück zum Zitat Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P (2011) Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9:344–350CrossRefPubMed Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P (2011) Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9:344–350CrossRefPubMed
12.
Zurück zum Zitat Shin Hyun-Jin, Lee Jee-Boong, Park Sung-Hwan, Chang Jun, Lee Chang-Woo (2009) T-bet expression is regulated by EGR1-mediated signaling in activated T cells. Clin Immunol 131:385–394CrossRefPubMed Shin Hyun-Jin, Lee Jee-Boong, Park Sung-Hwan, Chang Jun, Lee Chang-Woo (2009) T-bet expression is regulated by EGR1-mediated signaling in activated T cells. Clin Immunol 131:385–394CrossRefPubMed
13.
Zurück zum Zitat Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655–669CrossRefPubMed Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655–669CrossRefPubMed
14.
15.
Zurück zum Zitat Chung HT, Kim LH, Park BL, Lee JH, Park HS (2003) Association analysis of novel TBX21 variants with asthma phenotypes. Hum Mutat 22:252–257CrossRef Chung HT, Kim LH, Park BL, Lee JH, Park HS (2003) Association analysis of novel TBX21 variants with asthma phenotypes. Hum Mutat 22:252–257CrossRef
16.
Zurück zum Zitat Fyall KM, Fong AM, Rao SB, Ibrahim JG, Waxweiler WT, Thomas NE (2012) The TBX21 transcription factor T-1993C polymorphism is associated with decreased IFN-γ and IL-4 production by primary human lymphocytes. Hum Immunol 73:673–676CrossRefPubMedPubMedCentral Fyall KM, Fong AM, Rao SB, Ibrahim JG, Waxweiler WT, Thomas NE (2012) The TBX21 transcription factor T-1993C polymorphism is associated with decreased IFN-γ and IL-4 production by primary human lymphocytes. Hum Immunol 73:673–676CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Chen S, Zhao W, Tan W, Xu B, Dan Y, Mao Q, Kuang X, Wang Y, Deng G (2009) Association of TBX21 T-1993C polymorphism with viral persistence but not disease progression in hepatitis B virus carriers. Hepatol Res 39:716–723CrossRefPubMed Chen S, Zhao W, Tan W, Xu B, Dan Y, Mao Q, Kuang X, Wang Y, Deng G (2009) Association of TBX21 T-1993C polymorphism with viral persistence but not disease progression in hepatitis B virus carriers. Hepatol Res 39:716–723CrossRefPubMed
18.
Zurück zum Zitat Bergqvist A, Sundström S, Dimberg LY, Gylfe E, Masucci MG (2003) The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered Ca2+ oscillations. J Biol Chem 278:18877–18883CrossRefPubMed Bergqvist A, Sundström S, Dimberg LY, Gylfe E, Masucci MG (2003) The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered Ca2+ oscillations. J Biol Chem 278:18877–18883CrossRefPubMed
19.
Zurück zum Zitat Large MK, Kittlesen DJ, Hahn YS (1999) Suppression of host immune response by thecore protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 162:2931–2938 Large MK, Kittlesen DJ, Hahn YS (1999) Suppression of host immune response by thecore protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 162:2931–2938
20.
Zurück zum Zitat Walewski JL, Keller TR, Stump DD, Branch AD (2001) Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7:710–721CrossRefPubMedPubMedCentral Walewski JL, Keller TR, Stump DD, Branch AD (2001) Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7:710–721CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kong J, Deng X, Wang Z, Yang J, Zhang Y, Yu J (2009) Hepatitis C virus F protein: a double-sword in the potential contribution of chronic inflammation to carcinogenesis. Mol Med Rep 2:461–469PubMed Kong J, Deng X, Wang Z, Yang J, Zhang Y, Yu J (2009) Hepatitis C virus F protein: a double-sword in the potential contribution of chronic inflammation to carcinogenesis. Mol Med Rep 2:461–469PubMed
22.
Zurück zum Zitat Yue M, Deng X, Zhai X, Xu K, Kong J, Zhang J, Zhou Z, Yu X, Xu X, Liu Y, Zhu D, Zhang Y (2013) Th1 and Th2 cytokine profiles induced by hepatitis C virus F protein in peripheral blood mononuclear cells from chronic hepatitis C patients. Immunol Lett 152:89–95CrossRefPubMed Yue M, Deng X, Zhai X, Xu K, Kong J, Zhang J, Zhou Z, Yu X, Xu X, Liu Y, Zhu D, Zhang Y (2013) Th1 and Th2 cytokine profiles induced by hepatitis C virus F protein in peripheral blood mononuclear cells from chronic hepatitis C patients. Immunol Lett 152:89–95CrossRefPubMed
23.
Zurück zum Zitat Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC (1993) Sequence variability in the 5 non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 74:661–668CrossRefPubMed Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC (1993) Sequence variability in the 5 non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 74:661–668CrossRefPubMed
24.
Zurück zum Zitat Gaunt TR, Rodríguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’. BMC Bioinform 8:428CrossRef Gaunt TR, Rodríguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’. BMC Bioinform 8:428CrossRef
25.
Zurück zum Zitat Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, El-Mokhtar MA, Abdelwahab SF, Medhat A, Sherman KE, Shata MT (2016) Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Arch Virol 161:3161–3169CrossRefPubMedPubMedCentral Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, El-Mokhtar MA, Abdelwahab SF, Medhat A, Sherman KE, Shata MT (2016) Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Arch Virol 161:3161–3169CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Huang P, Yao Y, Yue M, Tian T, Chen H, Chen M, Wang J, Zhang Y, Yu R (2017) Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population. Sci Rep 7:42408CrossRefPubMedPubMedCentral Huang P, Yao Y, Yue M, Tian T, Chen H, Chen M, Wang J, Zhang Y, Yu R (2017) Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population. Sci Rep 7:42408CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Covolo L, Bibert S, Donato F, Bochud PY, Lagging M, Negro F, Fattovich G (2014) The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharmacol Ther 39:322–330CrossRefPubMed Covolo L, Bibert S, Donato F, Bochud PY, Lagging M, Negro F, Fattovich G (2014) The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharmacol Ther 39:322–330CrossRefPubMed
28.
Zurück zum Zitat Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo SI, Waked I, Thursz M, Abdelwahab SF (2015) Influence of IFNL3. rs12979860 and IFNL4. ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol Int 9:251–257CrossRefPubMed Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo SI, Waked I, Thursz M, Abdelwahab SF (2015) Influence of IFNL3. rs12979860 and IFNL4. ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol Int 9:251–257CrossRefPubMed
29.
Zurück zum Zitat Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P (2014) Polymorphisms of interferon-λ4 and IL28B effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 39:104–111CrossRefPubMed Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P (2014) Polymorphisms of interferon-λ4 and IL28B effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 39:104–111CrossRefPubMed
30.
Zurück zum Zitat Sultana C, Oprişan G, Teleman MD, Dinu S, HepGen 88/2012 Project Team, Oprea C, Voiculescu M, Ruta S (2016) Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. World J Gastroenterol 7:8406–8413CrossRef Sultana C, Oprişan G, Teleman MD, Dinu S, HepGen 88/2012 Project Team, Oprea C, Voiculescu M, Ruta S (2016) Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. World J Gastroenterol 7:8406–8413CrossRef
31.
Zurück zum Zitat Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR (2015) Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J 12:186CrossRefPubMedPubMedCentral Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR (2015) Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J 12:186CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Childs K, Merritt E, Considine A, Sanchez-Fueyo A, Agarwal K, Martinez-Llordella M, Carey I (2017) Immunological predictors of nonresponse to directly acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Open Forum Infect Dis 3:67 Childs K, Merritt E, Considine A, Sanchez-Fueyo A, Agarwal K, Martinez-Llordella M, Carey I (2017) Immunological predictors of nonresponse to directly acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Open Forum Infect Dis 3:67
Metadaten
Titel
Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C
verfasst von
Dan Yan Zhu
Xiao Zhao Deng
Yu Meng Zhu
Guo Tao Li
Guo Qiang Zhang
Ling Ju Wang
Jing Hai Zhang
Wen Xiao
Zhen Xian Zhou
Wei Liang Ding
Publikationsdatum
05.02.2018
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 5/2018
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-3750-9

Weitere Artikel der Ausgabe 5/2018

Archives of Virology 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.